Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,030 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CSF Clear all
Completed Phase 2 Interventional Results available

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

NCT00659789
View directory record Official record
Conditions
HIV I Infection
Interventions
Vacc-4x, Sterile water
Drug
Lead sponsor
Bionor Immuno AS
Industry
Eligibility
18 Years to 55 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Sacramento, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 28, 2026, 1:23 AM EDT
Not listed Phase 3 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00454168
View directory record Official record
Conditions
Leukemia
Interventions
PR1 leukemia peptide vaccine, sargramostim, placebo
Biological · Other
Lead sponsor
The Vaccine Company
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 1 Interventional

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

NCT00003060
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
16 Years to 44 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 28, 2026, 1:23 AM EDT
Recruiting No phase listed Observational

Cerebrospinal Fluid Biomarkers for Brain Tumors

NCT04692324
View directory record Official record
Conditions
Central Nervous System Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

NCT00075335
View directory record Official record
Conditions
Healthy
Interventions
AMD3100 (Mozobil plerixafor)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 28, 2026, 1:23 AM EDT
Recruiting Phase 2 Interventional

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

NCT06736613
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Stage III High Grade B-Cell Lymphoma, Stage IV High Grade B-Cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma of Breast, Diffuse Large B Cell Lymphoma of Testis, HIV-associated Diffuse Large B Cell Lymphoma, Double Expressor DLBCL
Interventions
Cerebral Spinal Fluid ctDNA
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Immunochemoradiotherapy in Patients With Pancreatic Cancer

NCT01342224
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
tadalafil and vaccination
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

NCT00088413
View directory record Official record
Conditions
Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
Interventions
PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine)
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Not applicable Interventional Results available

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

NCT00673179
View directory record Official record
Conditions
Osteosarcoma
Interventions
Doxorubicin, Cisplatin, Methotrexate, Leucovorin, Dexrazoxane, Ifosfamide, Questionnaire, Gemcitabine, Sargramostim, Surgery, Mesna
Drug · Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
5 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 28, 2026, 1:23 AM EDT
Not yet recruiting Not applicable Interventional

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

NCT06816979
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
Procedure · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 28, 2026, 1:23 AM EDT
Completed No phase listed Observational Results available

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

NCT01306890
View directory record Official record
Conditions
Advanced Prostate Cancer, Prostatic Neoplasms
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
333
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 245 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

NCT03597347
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Interventions
Molgramostim nebulizer solution, PARI eFlow nebulizer system
Drug · Device
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

NCT00352118
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, docetaxel, fluorouracil, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

NCT00007813
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 35 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 1 Interventional

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

NCT01403285
View directory record Official record
Conditions
Glioblastoma
Interventions
Cyclophosphamide, IMA950 plus GM-CSF, IMA950, Imiquimod
Drug · Biological
Lead sponsor
Immatics Biotechnologies GmbH
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

NCT00389818
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, immunohistochemistry staining method, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplant for Hematologic Diseases

NCT00058825
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Campath 1H, Fludarabine, Stem Cell Transplant, Total Body Irradiation (TBI), FK506 (Tacrolimus) or Cyclosporine
Biological · Drug · Procedure + 1 more
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

NCT00423852
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 1 Interventional Results available

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

NCT00278564
View directory record Official record
Conditions
MYOPATHY
Interventions
Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna, ATG(rabbit), Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 4 Interventional

ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients

NCT01323764
View directory record Official record
Conditions
Hydrocephalus
Interventions
ShuntCheck test
Device
Lead sponsor
NeuroDx Development
Industry
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

NCT00981799
View directory record Official record
Conditions
Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma
Interventions
Nelarabine, Etoposide, Cyclophosphamide, Methotrexate, Filgrastim
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 28, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

NCT00857389
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia, Lymphoma
Interventions
Thiotepa, Clofarabine, Busulfan, Allogeneic Stem Cell Transplantation, Thymoglobulin (ATG), G-CSF (Filgrastim), Tacrolimus, Methotrexate, Cyclophosphamide, Mesna
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 28, 2026, 1:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

NCT00048893
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim, sargramostim, cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, Mesna
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 28, 2026, 1:23 AM EDT
Withdrawn Phase 2 Interventional

A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

NCT05620914
View directory record Official record
Conditions
Brain Metastases, Adult
Interventions
Patritumab deruxtecan
Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 28, 2026, 1:23 AM EDT